Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

The acronym GLP-1 has become an increasingly popular term in the health arena, especially in the context of weight loss.

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

The president of Omada Health talks about why decision makers need to be thinking about holistic weight-management care as ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...